JP2022550954A5 - - Google Patents
Info
- Publication number
- JP2022550954A5 JP2022550954A5 JP2022520403A JP2022520403A JP2022550954A5 JP 2022550954 A5 JP2022550954 A5 JP 2022550954A5 JP 2022520403 A JP2022520403 A JP 2022520403A JP 2022520403 A JP2022520403 A JP 2022520403A JP 2022550954 A5 JP2022550954 A5 JP 2022550954A5
- Authority
- JP
- Japan
- Prior art keywords
- variant
- composition according
- expression construct
- composition
- related disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201914296A GB201914296D0 (en) | 2019-10-03 | 2019-10-03 | Treatment |
| GB1914296.7 | 2019-10-03 | ||
| PCT/GB2020/052435 WO2021064421A1 (en) | 2019-10-03 | 2020-10-02 | Treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022550954A JP2022550954A (ja) | 2022-12-06 |
| JP2022550954A5 true JP2022550954A5 (https=) | 2023-10-06 |
| JP7664233B2 JP7664233B2 (ja) | 2025-04-17 |
Family
ID=68541342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022520403A Active JP7664233B2 (ja) | 2019-10-03 | 2020-10-02 | 治療 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12331101B2 (https=) |
| EP (1) | EP4038098A1 (https=) |
| JP (1) | JP7664233B2 (https=) |
| CN (1) | CN114585742B (https=) |
| AU (1) | AU2020361079A1 (https=) |
| CA (1) | CA3156469A1 (https=) |
| GB (1) | GB201914296D0 (https=) |
| WO (1) | WO2021064421A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117677699A (zh) * | 2021-06-23 | 2024-03-08 | 马萨诸塞大学 | 用于治疗先兆子痫和其他血管生成病症的优化抗flt1寡核苷酸化合物 |
| CN121443737A (zh) * | 2023-12-05 | 2026-01-30 | 成都凌泰氪生物技术有限公司 | 一组特异性抑制雄激素受体的反义寡核苷酸及其应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2092323A1 (en) | 1990-10-01 | 1992-04-02 | George Y. Wu | Targeting viruses and cells for selective internalization by cells |
| ES2157225T3 (es) | 1992-10-09 | 2001-08-16 | Advanced Tissue Sciences Inc | Celulas hepaticas de reserva. |
| US20020165381A1 (en) * | 2000-11-30 | 2002-11-07 | Isabelle Ahrens-Fath | Human androgen receptor variants |
| DE10061161A1 (de) * | 2000-11-30 | 2002-06-20 | Schering Ag | Neue humane Androgenrezeptor-Varianten |
| JP2003102333A (ja) * | 2001-09-28 | 2003-04-08 | Yamanouchi Pharmaceut Co Ltd | ヒトアンドロゲン受容体発現ショウジョウバエ |
| US20050096284A1 (en) * | 2002-02-20 | 2005-05-05 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA) |
| WO2007041497A2 (en) * | 2005-09-30 | 2007-04-12 | Cleveland Biolabs, Inc. | Modulation of androgen receptor |
| WO2013102904A1 (en) * | 2012-01-05 | 2013-07-11 | Hadasit Medical Research Services & Development Ltd. | Methods and compositions for gene delivery |
| SMT201900735T1 (it) * | 2012-07-27 | 2020-03-13 | Aragon Pharmaceuticals Inc | Metodi e composizioni per determinare la resistenza a una terapia verso recettore degli androgeni |
| EP3696276A1 (en) * | 2013-02-25 | 2020-08-19 | Novartis AG | Novel androgen receptor mutation |
| WO2017070516A1 (en) * | 2015-10-22 | 2017-04-27 | University Of Massachusetts | Prostate-targeting adeno-associated virus serotype vectors |
| WO2017079570A2 (en) * | 2015-11-04 | 2017-05-11 | Duke University | Splise-switching oligonucleotides and methods of use |
| KR20190038797A (ko) * | 2016-06-09 | 2019-04-09 | 위스콘신 얼럼나이 리서어치 화운데이션 | Adt와 안드로겐 수용체 백신으로 구성된 조합 요법 |
| WO2019023651A2 (en) * | 2017-07-28 | 2019-01-31 | Massachusetts Institute Of Technology | MODULATORS OF THE SMALL MOLECULE ANDROGEN RECEPTOR |
-
2019
- 2019-10-03 GB GB201914296A patent/GB201914296D0/en not_active Ceased
-
2020
- 2020-10-02 CA CA3156469A patent/CA3156469A1/en active Pending
- 2020-10-02 CN CN202080069587.5A patent/CN114585742B/zh active Active
- 2020-10-02 JP JP2022520403A patent/JP7664233B2/ja active Active
- 2020-10-02 US US17/765,116 patent/US12331101B2/en active Active
- 2020-10-02 EP EP20788863.7A patent/EP4038098A1/en active Pending
- 2020-10-02 WO PCT/GB2020/052435 patent/WO2021064421A1/en not_active Ceased
- 2020-10-02 AU AU2020361079A patent/AU2020361079A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11759506B2 (en) | AADC polynucleotides for the treatment of Parkinson's disease | |
| US12319929B2 (en) | Compositions and methods for the treatment of Parkinson's disease | |
| RU2697444C2 (ru) | Вариант aav, композиции и способы, в которых он используется, а также способы его применения для переноса генов в клетки, органы и ткани | |
| JP2016500519A5 (https=) | ||
| JP2021530548A (ja) | 遺伝子治療製剤を生産するための系および方法 | |
| JP2023540054A5 (https=) | ||
| WO2021007382A1 (en) | Compositions and methods for the treatment of parkinson's disease | |
| JP2022550954A5 (https=) | ||
| CN107405315A (zh) | 用于治疗神经肌肉、神经变性、自身免疫、发育和/或代谢疾病的脑源性神经营养因子(bdnf)的诱导表达 | |
| JP2024517143A5 (https=) | ||
| JP2022512589A5 (https=) | ||
| JP2024119830A5 (https=) | ||
| JP2020514305A5 (https=) | ||
| JP2024545186A5 (https=) | ||
| JP2020527167A5 (https=) | ||
| JP2022060514A (ja) | ガバペンチノイドからの干渉が減少し、ｈｇｆ異型体を発現するｄｎａコンストラクトを用いる神経病症の治療 | |
| JP2022548217A5 (https=) | ||
| JP2024511066A5 (https=) | ||
| JP2023513487A5 (https=) | ||
| US12415850B2 (en) | Compositions and methods for regulating production of an antibody like protein and ribonucleic acid | |
| EP3215178A1 (en) | Treatment of cns inflammatory disorders | |
| JP2024528997A (ja) | 放射線誘発性唾液機能低下を予防するためのａｑｐ１遺伝子療法 | |
| CN114917342A (zh) | Arhgap44促进剂在抑制阿片类药物诱发的痛觉过敏中的应用 | |
| JP2023525476A5 (https=) | ||
| JP4533144B2 (ja) | 聴覚機能障害用医薬 |